Cargando…

Eradication rate and safety of a “simplified rescue therapy”: 14‐day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real‐world, retrospective clinical study in China

BACKGROUND: The currently recommended quadruple regimens as rescue therapy on Helicobacter pylori infection were not as effective as being supposed, especially in those who had failed two or more times. Dual regimen composed of vonoprazan (a potassium‐competitive acid blocker) and amoxicillin might...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Wen, Teng, Guigen, Wang, Chi, Xu, Ying, Li, Yixuan, Cheng, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542484/
https://www.ncbi.nlm.nih.gov/pubmed/35877765
http://dx.doi.org/10.1111/hel.12918
_version_ 1784804160581926912
author Gao, Wen
Teng, Guigen
Wang, Chi
Xu, Ying
Li, Yixuan
Cheng, Hong
author_facet Gao, Wen
Teng, Guigen
Wang, Chi
Xu, Ying
Li, Yixuan
Cheng, Hong
author_sort Gao, Wen
collection PubMed
description BACKGROUND: The currently recommended quadruple regimens as rescue therapy on Helicobacter pylori infection were not as effective as being supposed, especially in those who had failed two or more times. Dual regimen composed of vonoprazan (a potassium‐competitive acid blocker) and amoxicillin might be an option since it's effective in eradication therapy as first‐line treatment. OBJECTIVE: As a real‐world retrospective study, data were collected to evaluate the efficacy and safety of vonoprazan and amoxicillin dual regimen as rescue therapy in Helicobacter pylori positive patients who had failed one or more times in their previous treatment. METHODS: From May 2020 to June 2021, the clinical data of patients who had failed in Helicobacter pylori infection treatment were collected in GI department of Peking University First Hospital, Beijing, China. Patients were given vonoprazan 20 mg or 40 mg per day and amoxicillin 3000 mg per day (VA dual therapy) for 14 days as rescue treatment. Helicobacter pylori status was evaluated by (13)C‐urease breath test 6 weeks after treatment. All adverse effects during treatment were recorded. RESULTS: A total of 186 patients were enrolled, including 67 males and 119 females. All of them had failed for 1 ~ 7 times in their previous treatment. Successful eradication was achieved in 172 patients (92.5%, 172/186). The adverse effects (referring to skin rash, abdominal pain, diarrhea, and headache), mainly mild and did not cause quit of treatment, occurred in 14 patients (7.5%, 14/186) and all symptoms relieved spontaneously. CONCLUSIONS: Dual regimen composed of vonoprazan and amoxicillin for 14 days was effective and safe as rescue therapy in Helicobacter pylori infection treatment. It could be chosen as a “simplified rescue therapy” with relatively high eradication rate no matter how many times the patients had failed and what regimens they had used previously.
format Online
Article
Text
id pubmed-9542484
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95424842022-10-14 Eradication rate and safety of a “simplified rescue therapy”: 14‐day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real‐world, retrospective clinical study in China Gao, Wen Teng, Guigen Wang, Chi Xu, Ying Li, Yixuan Cheng, Hong Helicobacter Original Articles BACKGROUND: The currently recommended quadruple regimens as rescue therapy on Helicobacter pylori infection were not as effective as being supposed, especially in those who had failed two or more times. Dual regimen composed of vonoprazan (a potassium‐competitive acid blocker) and amoxicillin might be an option since it's effective in eradication therapy as first‐line treatment. OBJECTIVE: As a real‐world retrospective study, data were collected to evaluate the efficacy and safety of vonoprazan and amoxicillin dual regimen as rescue therapy in Helicobacter pylori positive patients who had failed one or more times in their previous treatment. METHODS: From May 2020 to June 2021, the clinical data of patients who had failed in Helicobacter pylori infection treatment were collected in GI department of Peking University First Hospital, Beijing, China. Patients were given vonoprazan 20 mg or 40 mg per day and amoxicillin 3000 mg per day (VA dual therapy) for 14 days as rescue treatment. Helicobacter pylori status was evaluated by (13)C‐urease breath test 6 weeks after treatment. All adverse effects during treatment were recorded. RESULTS: A total of 186 patients were enrolled, including 67 males and 119 females. All of them had failed for 1 ~ 7 times in their previous treatment. Successful eradication was achieved in 172 patients (92.5%, 172/186). The adverse effects (referring to skin rash, abdominal pain, diarrhea, and headache), mainly mild and did not cause quit of treatment, occurred in 14 patients (7.5%, 14/186) and all symptoms relieved spontaneously. CONCLUSIONS: Dual regimen composed of vonoprazan and amoxicillin for 14 days was effective and safe as rescue therapy in Helicobacter pylori infection treatment. It could be chosen as a “simplified rescue therapy” with relatively high eradication rate no matter how many times the patients had failed and what regimens they had used previously. John Wiley and Sons Inc. 2022-07-25 2022-10 /pmc/articles/PMC9542484/ /pubmed/35877765 http://dx.doi.org/10.1111/hel.12918 Text en © 2022 The Authors. Helicobacter published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Gao, Wen
Teng, Guigen
Wang, Chi
Xu, Ying
Li, Yixuan
Cheng, Hong
Eradication rate and safety of a “simplified rescue therapy”: 14‐day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real‐world, retrospective clinical study in China
title Eradication rate and safety of a “simplified rescue therapy”: 14‐day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real‐world, retrospective clinical study in China
title_full Eradication rate and safety of a “simplified rescue therapy”: 14‐day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real‐world, retrospective clinical study in China
title_fullStr Eradication rate and safety of a “simplified rescue therapy”: 14‐day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real‐world, retrospective clinical study in China
title_full_unstemmed Eradication rate and safety of a “simplified rescue therapy”: 14‐day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real‐world, retrospective clinical study in China
title_short Eradication rate and safety of a “simplified rescue therapy”: 14‐day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real‐world, retrospective clinical study in China
title_sort eradication rate and safety of a “simplified rescue therapy”: 14‐day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of helicobacter pylori infection previously failed in eradication: a real‐world, retrospective clinical study in china
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542484/
https://www.ncbi.nlm.nih.gov/pubmed/35877765
http://dx.doi.org/10.1111/hel.12918
work_keys_str_mv AT gaowen eradicationrateandsafetyofasimplifiedrescuetherapy14dayvonoprazanandamoxicillindualregimenasrescuetherapyontreatmentofhelicobacterpyloriinfectionpreviouslyfailedineradicationarealworldretrospectiveclinicalstudyinchina
AT tengguigen eradicationrateandsafetyofasimplifiedrescuetherapy14dayvonoprazanandamoxicillindualregimenasrescuetherapyontreatmentofhelicobacterpyloriinfectionpreviouslyfailedineradicationarealworldretrospectiveclinicalstudyinchina
AT wangchi eradicationrateandsafetyofasimplifiedrescuetherapy14dayvonoprazanandamoxicillindualregimenasrescuetherapyontreatmentofhelicobacterpyloriinfectionpreviouslyfailedineradicationarealworldretrospectiveclinicalstudyinchina
AT xuying eradicationrateandsafetyofasimplifiedrescuetherapy14dayvonoprazanandamoxicillindualregimenasrescuetherapyontreatmentofhelicobacterpyloriinfectionpreviouslyfailedineradicationarealworldretrospectiveclinicalstudyinchina
AT liyixuan eradicationrateandsafetyofasimplifiedrescuetherapy14dayvonoprazanandamoxicillindualregimenasrescuetherapyontreatmentofhelicobacterpyloriinfectionpreviouslyfailedineradicationarealworldretrospectiveclinicalstudyinchina
AT chenghong eradicationrateandsafetyofasimplifiedrescuetherapy14dayvonoprazanandamoxicillindualregimenasrescuetherapyontreatmentofhelicobacterpyloriinfectionpreviouslyfailedineradicationarealworldretrospectiveclinicalstudyinchina